Viewing Study NCT05472506

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-26 @ 11:00 AM
Ignite Modification Date: 2026-01-13 @ 9:37 AM
Study NCT ID: NCT05472506
Status: WITHDRAWN
Last Update Posted: 2024-03-15
First Post: 2022-07-20
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Oral AHR Antagonist in Combination With Nivolumab in Patients With PD-1 Resistant Metastatic or Recurrent Head and Neck Cancer
Sponsor: Ikena Oncology
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Head and Neck Squamous Cell Carcinoma View
None Head and Neck Cancer View
None Head Cancer View
None Neck Cancer View
None Head Cancer Neck View
None Neck Carcinoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None IK-175 View
None AHR antagonist View
None AHR inhibitor View
None Aryl Hydrocarbon Receptor Antagonist View
None Immunooncology View
None AHRi View
None Aryl Hydrocarbon Receptor Inhibitor View
None Antagonist View
None Inhibitor View
None anti-PD1 View
None aPD1 View
None nivolumab View
None checkpoint inhibitor View
None CPI View
None combination therapy View